Jupiter Medical Center’s Clinical Research Department has opened a new clinical trial partnering with the Margaret W. Niedland Breast Center.

The trial is sponsored by the Cancer and Leukemia Group B (CALGB) for breast cancer prevention in women. Only a few sites in the country are offering this study and include; Dana Farber Cancer Institute, University of Vermont and Ohio State University.

Participation is limited to 250 patients nationwide and Jupiter Medical Center’s research department anticipates quick enrollment.

Currently, there are limited breast cancer prevention options. Studies have shown that there is a reduction of breast cancer risk in women with increased intake of Vitamin D.

The Vitamin D and Breast Cancer Biomarkers trial, sponsored by CALGB, is looking at various factors that correlate with increased chances of breast cancer and the effect that Vitamin D has on this factor.

The most notable factor is a woman’s breast density which is discovered by mammography. Mammographic breast density is a strong risk factor for development of breast cancer.
To be eligible to participate in the trial, female participants must be premenopausal, under the age of 55, have a breast density diagnosis of above 25%, and be willing to take Vitamin D or a placebo daily for 12 months.

Jupiter Medical Center and the Margaret W. Niedland Breast Center are pleased and excited to offer this clinical trial to the community.
If you are interested in participating in this trial or for more information, please contact Jeanine Secor RN, BSN, CCRP, Jupiter Medical Center Clinical Research Manager, at 561.263.5791.